In Riyadh, Saudi Arabia, King Faisal Specialist Hospital has launched the Kingdom's first facility for manufacturing gene and cell therapies. The initiative aims to provide patients with accessible treatment and achieve savings estimated at around eight billion riyals by 2030. The facility, covering an area of over 5,000 square meters within the hospital campus, is scheduled to begin operations in late 2025. Its production will include advanced immune-based therapies such as T-cells, stem cells, and viral vector technologies. The facility is set to expand in the future to include gene-editing techniques and the production of liver and pancreatic cells to treat complex genetic and immune diseases. By 2030, the annual production capacity is expected to reach approximately 2,400 therapeutic doses. The facility operates according to Good Manufacturing Practice (GMP) standards, which are the global gold standard, ensuring that therapies are produced in a highly controlled and precise environment where every step is reviewed and every process is documented to deliver the treatment to the patient with the highest levels of safety and quality. Furthermore, the facility is distinguished by its integration of smart manufacturing technologies and artificial intelligence into quality control and production.
